Short communication: Amitraz treatments do not increase the frequency of mutations in the β2-adrenergic octopamine receptor in Varroa destructor: a field study in Central Spain | Synapse
March 3, 2026
Short communication: Amitraz treatments do not increase the frequency of mutations in the β2-adrenergic octopamine receptor in Varroa destructor: a field study in Central Spain
Puntos clave
No increase in β2-adrenergic octopamine receptor mutations was observed from amitraz treatments.
Testing revealed no significant mutations in Varroa destructor after exposure to amitraz in the field.
Field study conducted in Central Spain assessed the genetic effects of amitraz on the target species.
Findings imply that amitraz use may be safe regarding genetic mutation risks for Varroa destructor.